Effient

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2017
012320082017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
INTRODUCTION A 76-year-old male presented to the emergency department complaining of intense abdominal pain. He reported one week… (More)
  • figure 1
  • figure 2
Is this relevant?
Review
2013
Review
2013
INTRODUCTION Dual antiplatelet therapy (DAPT) with aspirin and a thienopyridine (eg, clopidogrel) prevents stent related… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2013
2013
Dermatology topics include agents for psoriasis, urticaria, and infantile hemangiomas. The pros and cons of antiplatelet drugs… (More)
Is this relevant?
Review
2013
Review
2013
A recent occurrence in dental practice is the noting of new "blood thinners" when the clinician is reviewing a patient's medical… (More)
Is this relevant?
Review
2013
Review
2013
Volume 88, Number 12 www.aafp.org/afp American Family Physician 821 Ticagrelor (Brilinta) is a newer, reversible P2Y12 platelet… (More)
Is this relevant?
2011
2011
  • The Medical letter on drugs and therapeutics
  • 2011
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the… (More)
Is this relevant?
2010
2010
An algorithm for use of Prasugrel (Effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Review
2009
Review
2009
  • The Medical letter on drugs and therapeutics
  • 2009
The FDA has approved prasugrel (Effient--Lilly/Daiichi Sankyo), an oral antiplatelet drug, for use with aspirin to reduce the… (More)
Is this relevant?
2009
2009
Prasugrel (Effient) has been approved for reducing the risk of thrombotic complications in patients with acute coronary syndromes… (More)
Is this relevant?
Review
2008
Review
2008
Prasugrel, trade name Effient, is an investigational new antiplatelet drug currently under review for clinical use by the Food… (More)
  • figure 1
Is this relevant?